Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aytu Biopharma Inc AYTU

Healthcare
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended... see more

Recent & Breaking News (NDAQ:AYTU)

Aytu BioScience and Innovus Pharmaceuticals Announce Effectiveness of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience

Accesswire January 27, 2020

Aytu BioScience and Innovus Pharmaceuticals Announce Filing of Form S-4 Registration Statement Related to Proposed Acquisition of Innovus by Aytu BioScience

Accesswire December 24, 2019

Rigrodsky & Long, P.A. Files Class Action Suit Against Aytu BioScience, Inc.

GlobeNewswire December 17, 2019

INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Following Transaction

ACCESSWIRE IA December 14, 2019

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers

GlobeNewswire December 12, 2019

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation Regarding the November 21, 2019 Preliminary Proxy Statement of AYTU BIOSCIENCE, INC. - AYTU

PR Newswire December 12, 2019

MiOXSYS Male Infertility Test Will be Featured in Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine

Accesswire December 5, 2019

Aytu BioScience to Present at LD Micro 12th Annual Main Event Investor Conference on December 11, 2019

Accesswire December 3, 2019

Aytu BioScience Announces Launch of Natesto(R) U.S. Co-Promotion with Acerus Pharmaceuticals

Accesswire December 2, 2019

Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading Pharmacy Benefit Manager's National Formulary

Accesswire November 19, 2019

Aytu Reports First Quarter 2020 Financial Results

Accesswire November 14, 2019

Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations

Accesswire November 11, 2019

Aytu BioScience to Report Fiscal Q1 FY 2020 Results and Business Update

Accesswire November 7, 2019

Kaskela Law LLC Announces Stockholder Investigation of Aytu BioScience, Inc. - AYTU

GlobeNewswire November 4, 2019

Aytu BioScience Announces Closing of $12.4M Prescription Product Portfolio Purchase

Accesswire November 4, 2019

Aytu BioScience Announces Addition of Tuzistra(R) XR to Leading National Pharmacy Benefit Manager's Formulary

Accesswire October 21, 2019

Aytu BioScience Announces Positive Clinical Results from Natesto(R) Spermatogenesis Study

Accesswire October 17, 2019

Aytu BioScience to Announce Results from Natesto(R) Spermatogenesis Study on Thursday, October 17

Accesswire October 16, 2019

Aytu BioScience Acquires $12.4 Million Prescription Product Portfolio

Accesswire October 14, 2019

Aytu BioScience Announces $10 Million Private Placement

Accesswire October 14, 2019